Fig 2A and 2D indicated that DR5 expression was elevated in multiple glioblastoma cell lines. A low dose of lovastatin (2.5 μM) is sufficient to up-regulate DR5 expression in these cell lines. We next examined NF-κB activity in U87 cells treated with lovastatin using a dual-luciferase reporter assay. Fig 2B showed that 20 μM lovastatin significantly reduced NF-κB activity in U87 cells (Fig 2B). This evidence concerns the gene NFKB1 and glioblastoma.